Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications primarily in the United States. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

Sintx Technologies, Inc.

SINTX Technologies is an OEM ceramics company that develops and commercializes advanced ceramics for medical and non-medical applications. The core strength of SINTX Technologies is the manufacturing, research, and development of advanced ceramics for external partners. 

We are a 25-year-old company that started as a spine company and have grown over time to become an advanced ceramics company engaged in many different fields, which enabled us to focus on our core competencies. Our key business segments of focus are the use of advanced ceramics for antipathogenic, biomedical, armor and industrial applications. SINTX frequently connects with new customers, partners, and manufacturers to help realize our goal of leveraging our expertise in high-tech ceramics to create new, innovative opportunities across these sectors.

We presently manufacture advanced ceramic powders and components in our manufacturing facility based in Salt Lake City, Utah.

GE Capital

Zions First National Bank

Magna

Hercules Capital

Creation Capital

SINTX Technologies

SINTX congratulates CTL Amedica on the first implantation of this new silicon nitride spinal interbody fusion device!

SINTX significantly strengthens its antipathogenic patent portfolio with six United States patent within the last year.  

https://lnkd.in/gGsbVi5k

Another patent has been issued to SINTX!  This one is titled "Antipathogenic Face Mask" and is US patent number 11,857,001.  The patent stipulates the use of a face mask that contains 1 to 15 wt.% silicon nitride powder and is capable of inactivating a human virus on contact.

US patent 11,850,214 was issued to SINTX on December 26, 2023. The patent is titled “Antiviral Compositions and Devices and Methods of Use Thereof.” This is a broader based patent than US 11,844,344. It claims that silicon nitride when combined with another material at a composition range of 1 to 15 wt.% of a silicon nitride material (e.g., α- and ß-Si3N4, SiYAlON, ß-SiYALON, SiYON, or SiAlON), is effective in inactivating human viruses within 30 minutes. This antiviral composition can comprise a slurry, suspension, spray, gel, paint, or toothpaste. This composition can be applied to any number of medical devices or personal protective equipment.

SINTX is pleased to report that the 4th US patent this year has been granted to the company. The patent (US#11,844,344) is titled Systems and Methods for Rapid Inactivation of SARS-COV-2 by Silicon Nitride and Aluminum Nitride. This patent provides broad coverage for medical-related and personal protective equipment against essentially all human pathogenic viruses. 

The patent specifically claims that 1 wt.% to 30 wt.% compositions of silicon nitride powder with a particle size between 0.6 µm and 5 µm are effective in inactivating human viruses when incorporated into an object or as a coating on an object such as a protective gown, a body cover, a head cover, a shoe cover, a face mask, a face shield, an eye protector, gloves, a surgical gown, a surgical drape, a cubicle curtain, a face mask filter, a respirator filter, an air filtration filter, an air ventilation filter, a knob, a handle, a railing, a bed frame, a bed tray, a table, a chair, an equipment rack, a cabinet, or a cart. The silicon nitride composition may comprise a slurry, suspension, gel, paint, toothpaste, and may be sprayed onto the surface of the object.  

SINTX stands ready to discuss the application of these technologies to produce improved products for our customers.

SINTX is excited to support CTL with this new product launch!

The Air Force Research Lab (AFRL) Regional Hub – Mid-Atlantic has announced that it has selected a collaboration between SINTX, Moog, Inc., and Cornell University to receive funding for a proposal on “Additive Manufacturing of Advanced Ceramics.” The team is working on an AF Hub phase II program to develop a new, additively manufactured monolithic ceramic combustor to replace an expensive, long lead time refractory metal component. Silicon Nitride is an ideal material for the component because of its thermal and mechanical properties. The new combustor is to be used in an ESPA class satellite and designed specifically to work with the new AF propellent, ASCENT.

https://lnkd.in/eYdHedBd

It was a great experience supporting the life science industry in Utah!

SINTX VP of R&D, Dr. Ryan Bock, attended Formnext in Frankfurt, Germany this week. Formnext is the largest gathering of additive manufacturing, rapid prototyping, and 3D printing professionals in the world. While there, Dr. Bock was able to meet with a wide variety of current and potential new suppliers, partners, and customers related to SINTX’s specialties in ceramic and polymer composite additive manufacturing and prototyping.

We're proud of this accomplishment and are celebrating our first long term supply agreement in the aerospace industry. 

https://lnkd.in/gPXfHMx2

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	22.31M -	22.77M 2.02%	19.45M 14.55%	15.23M 21.73%	11.23M 26.26%	95K 99.15%	689K 625.26%	594K 13.79%	606K 2.02%	601K 0.83%	2.63M 337.10%
cost of revenue	7.04M -	7.91M 12.28%	6.25M 20.99%	3.78M 39.57%	6.35M 68.18%	56K 99.12%	551K 883.93%	475K 13.79%	449K 5.47%	265K 40.98%	2.44M 821.13%
gross profit	15.27M -	14.86M 2.71%	13.20M 11.12%	11.45M 13.28%	4.88M 57.42%	39K 99.20%	138K 253.85%	119K 13.77%	157K 31.93%	336K 114.01%	186K 44.64%
selling and marketing expenses	16.38M -	18.69M 14.09%	12.42M 33.55%	10.35M 16.70%	6.47M 37.45%	135K 97.91%	430K 218.52%	683K 58.84%	1.29M 88.58%	1.34M 3.73%	1.14M 14.90%
general and administrative expenses	5.76M -	13.59M 135.94%	6.44M 52.63%	6.29M 2.24%	4.38M 30.39%	4.55M 3.84%	2.91M 36.06%	4.38M 50.55%	3.60M 17.70%	3.99M 10.74%	4.22M 5.81%
selling general and administrative expenses	22.14M -	32.28M 45.78%	18.86M 41.58%	16.64M 11.76%	10.85M 34.78%	4.68M 56.85%	3.34M 28.72%	5.06M 51.62%	4.89M 3.36%	5.33M 8.89%	3.70M 30.49%
research and development expenses	3.46M -	6.74M 94.80%	6.39M 5.27%	6.34M 0.66%	5.08M 19.98%	2.99M 41.09%	3.39M 13.47%	4.81M 41.66%	5.89M 22.42%	6.45M 9.58%	8.71M 35.09%
other expenses						83K -	48K 42.17%	282K 487.50%	1.05M 271.63%	-105K 110.02%	-1.13M 975.24%
cost and expenses	32.65M -	46.93M 43.75%	31.49M 32.89%	26.76M 15.03%	22.28M 16.74%	7.73M 65.31%	7.28M 5.78%	10.34M 42.03%	11.23M 8.53%	11.94M 6.32%	15.98M 33.92%
operating expenses	25.60M -	39.02M 52.41%	25.24M 35.31%	22.98M 8.95%	15.93M 30.70%	7.67M 51.82%	6.73M 12.28%	9.87M 46.60%	10.78M 9.20%	11.67M 8.30%	13.54M 16.05%
interest expense	1.85M -	3.65M 97.19%	4.34M 18.88%	4.51M 3.96%	1.26M 72.00%	1.39M 9.90%	4K 99.71%	2K 50%	25K 1,150%	17K 32%	2K 88.24%
ebitda	-8.11M -	-24.16M 197.77%	-10.71M 55.67%	-9.60M 10.37%	-10.07M 4.91%	-7.44M 26.09%	-5.63M 24.41%	-8.64M 53.57%	-8.82M 2.09%	-9.97M 12.99%	-11.70M 17.40%
operating income	-10.34M -	-24.17M 133.84%	-12.04M 50.18%	-11.54M 4.20%	-11.05M 4.18%	-13.12M 18.66%	-6.59M 49.73%	-9.75M 47.86%	-10.62M 8.92%	-11.34M 6.73%	-13.36M 17.85%
depreciation and amortization	2.21M -	2.34M 6.03%	2.15M 7.99%	1.94M 10.08%	1.11M 42.46%	109K 90.22%	968K 788.07%	1.11M 14.67%	1.80M 62.07%	1.37M 23.96%	1.66M 21.13%
total other income expenses net	3.88M -	-4.78M 222.99%	-6.71M 40.49%	-552K 91.77%	3.12M 664.86%	-666K 121.36%	1.80M 369.82%	2.72M 51.42%	1.84M 32.19%	-704K 138.16%	5.10M 824.29%
income before tax	-8.29M -	-32.58M 293.22%	-23.91M 26.61%	-16.60M 30.59%	-9.33M 43.79%	-9.69M 3.86%	-4.80M 50.49%	-7.03M 46.53%	-8.78M 24.84%	-12.04M 37.20%	-8.26M 31.40%
income tax expense	1.85M -	1.31M 29.23%	4.34M 231.22%	6.28M 44.69%	1.26M 79.88%	4.82M 281.24%	52K 98.92%	284K 446.15%	1.05M 269.01%	4.45M 324.62%	26K 99.42%
net income	-8.29M -	-32.58M 293.22%	-23.91M 26.61%	-16.60M 30.59%	-9.33M 43.79%	-8.65M 7.26%	-4.85M 43.96%	-7.31M 50.81%	-9.82M 34.32%	-16.49M 67.86%	-8.26M 49.91%
weighted average shs out							15.56K -	164.06K 954.47%	2.47K 98.49%	301.61K 12,114.94%	3.74M 1,138.82%
weighted average shs out dil							15.56K -	174.46K 1,021.29%	2.51K 98.56%	317.32K 12,557.43%	4.36M 1,273.13%
eps							-311.65 -	-44.57 85.70%	-3.98K 8,825.80%	-54.67 98.63%	-2.21 95.96%
epsdiluted							-311.65 -	-41.92 86.55%	-3.92K 9,246.88%	-51.96 98.67%	-1.90 96.34%

COM:SINTX

SINTX Technologies Inc

Last Close

4.97

26/07 17:56

Market Cap

3.06M

Beta: -

Volume Today

104.22K

Avg: -

Preview